Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633235 | 0.91 | KMT2A (0.45) | KMT2AMEN1GPR119MMP13NAMPT | |
| SCHEMBL16633236 | 0.91 | KMT2A (0.45) | KMT2AMEN1GPR119MMP13NAMPT | |
| SCHEMBL13832628 | 0.91 | GPR119 (0.51) | KMT2AMEN1GPR119MMP13STS | |
| SCHEMBL13832841 | 0.91 | GPR119 (0.51) | KMT2AMEN1GPR119MMP13STS | |
| SCHEMBL1502200 | 0.91 | GPR119 (0.51) | KMT2AMEN1GPR119MMP13STS | |
| SCHEMBL31282646 | 0.90 | KMT2A (0.47) | KMT2AMEN1GPR119MMP13NR1H2 | |
| SCHEMBL344238 | 0.89 | SCN9A (0.49) | KMT2AMEN1GPR119MMP13 | |
| SCHEMBL344239 | 0.89 | SCN9A (0.49) | KMT2AMEN1GPR119MMP13 | |
| SCHEMBL9068325 | 0.89 | SCN9A (0.49) | KMT2AMEN1GPR119MMP13 | |
| SCHEMBL4828186 | 0.88 | GPR119 (0.47) | KMT2AMEN1GPR119MMP13NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12409177-B2 | FGFR inhibitors for the treatment of cancer | BRIDGENE BIOSCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119255990-A | Nitrogen-containing five-membered heterocyclic derivative as checkpoint kinase 1 inhibitor and application thereof | 曙方医药 | 2025-01-03 | — | — | CN | disclosed |
| CN-115666575-B | Compounds and uses thereof | 福宏治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-11981683-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009104729-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 大日本住友製薬株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
| EP-1831173-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | US | disclosed |
| WO-2006066197-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | KMT2A 1251/4885MEN1 2327/4885GPR119 2318/4885 |
| US-12409177-B2 | FGFR inhibitors for the treatment of cancer | FGFR4, FGFR2, FGFR1 | KMT2A 502/4885MEN1 4263/4885GPR119 1787/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | KMT2A 1480/4885MEN1 3113/4885GPR119 3678/4885 |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | KMT2A 1251/4885MEN1 2327/4885GPR119 2318/4885 |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | HRH3, HRH4, HRH1 | KMT2A 494/4885MEN1 1264/4885GPR119 163/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | KMT2A 1251/4885MEN1 2327/4885GPR119 2318/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | KMT2A 865/4885MEN1 1946/4885GPR119 2190/4885 |
| US-11981683-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | KMT2A 1251/4885MEN1 2327/4885GPR119 2318/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | KMT2A 2738/4885MEN1 2621/4885GPR119 23/4885 |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | KMT2A 3267/4885MEN1 1304/4885GPR119 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.